GFAP and myeloid sarcoma: These differences could be observed in the chronic stage of the model, in which acute inflammation has subsided but neurodegeneration/neuroinflammation remain detectable in the mouse CNS as evidenced by MS-relevant biomarkers such as GFAP and NF-L in the CSF.